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E-mail address: s.mandrup@bmb.sdu.dk (S. MandrAdipocyte differentiation is controlled by a tightly regulated transcriptional cascade in which PPARc
and members of the C/EBP family are key players. Here we review the roles of PPARc and C/EBPs in
adipocyte differentiation with emphasis on the recently published genome-wide binding proﬁles for
PPARc and C/EBPa. Interestingly, these analyses show that PPARc and C/EBPa binding sites are asso-
ciated with most genes that are induced during adipogenesis suggesting direct activation of many
more adipocyte genes than previously anticipated. Furthermore, an extensive overlap between
the C/EBPa and PPARc cistromes indicate a hitherto unrecognized direct crosstalk between these
transcription factors. As more genome-wide data emerge in the future, this crosstalk will likely
be found to include several other adipogenic transcription factors.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Obesity and type 2 diabetes mellitus
During the last two decades the incidence of obesity and type 2
diabetes mellitus (T2DM) has increased rapidly worldwide. Conse-
quently, huge efforts are being made to elucidate the mechanisms
underlying adipose tissue development and the pathology of obes-
ity. In a normal healthy person, white adipose tissue stores excess
energy in the form of fat. When energy intake is scarce, this fat can
be released as fatty acids into the blood stream, where it can be ta-
ken up by other tissues (e.g. liver and skeletal muscle) and used as
an alternative energy source. When energy intake consistently ex-
ceeds energy expenditure, the adipose tissue expands due to
hypertrophy in particular but also due to hyperplasia of the adipo-
cytes. The hypertrophied adipocytes secrete adipokines which may
directly interfere with insulin signaling and which have also been
shown to recruit macrophages that induce an inﬂamed state in
the adipose tissue. The macrophages secrete high amounts of
pro-inﬂammatory cytokines, which further exacerbates insulin
resistance of the adipocytes, and causes a decrease in the net ﬂux
of fatty acids into the adipocytes. This results in an increased depo-
sition of fatty acids as triacylglycerides in non-adipose tissues such
as the liver, skeletal muscle, and pancreas. A large body of litera-chemical Societies. Published by E
Biochemistry and Molecular
5, 5230 Odense M, Denmark.
up).ture has demonstrated that such ectopic deposition of fatty acids
causes metabolic overload and stress that through various signal-
ing pathways lead to insulin resistance in these tissues. Systemic
insulin resistance increases the demand for insulin production,
and T2DMmay develop if the demand exceeds the secretory capac-
ity of the b-cells. In addition to T2DM, obesity is often associated
with cardiovascular diseases such as atherosclerosis, which is char-
acterized by cholesterol accumulation in macrophages leading to
the formation of foam cells and plaques in the arterial wall. These
physiological and metabolic responses to obesity have been exten-
sively reviewed elsewhere [1–4].
In keeping with the central role of adipocytes in maintaining
whole body insulin sensitivity, drugs that target the nuclear recep-
tor peroxisome proliferator-activated receptor c (PPARc), which is
an important transcription factor in the development and function
of the adipose tissue (see below), have been shown to function as
potent insulin sensitizers. Activation of PPARc in the adipose tissue
by compounds such as thiazolidinediones (TZDs) leads to increased
storage capacity of fatty acids in the adipocytes and thereby a de-
crease in the amount of circulating fatty acids [3,5]. In addition,
PPARc activates the expression of adiponectin, which is involved
in the sensitization of liver and muscle to insulin [6]. Furthermore,
liganded PPARc antagonizes the function of pro-inﬂammatory
transcription factors such as nuclear factor-jB (NF-jB), thereby
decreasing the expression of pro-inﬂammatory cytokines and
diminishing the inﬂamed state in the adipose tissue [3]. Finally,
activation of PPARc has been shown to lead to increased de novolsevier B.V. All rights reserved.
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smaller and more insulin sensitive adipocytes [7]. Interestingly, re-
cent data indicate that PPARc agonists may also promote a more
brown adipocyte-like phenotype with increased mitochondrial
capacity and increased uncoupling potential [8–10]. Thus, the adi-
pose tissue is an important regulator of whole body metabolism
and a central target tissue in the treatment of insulin resistance
and T2DM.
2. Roles of PPARc and C/EBPs during adipogenesis
Adipogenesis is a tightly controlled process that involves an
intricate network of transcription factors acting at different time
points during differentiation [11,12]. Several studies have clearly
established PPARc as a key regulator of adipocyte development
both in vitro and in vivo. This receptor is known to be obligate
for adipocyte differentiation [13,14] and in many cases sufﬁcient
to convert non-adipose cells to adipocyte-like cells [15,16]. PPARs
are members of the nuclear receptor superfamily and character-
ized as adopted orphan receptors, which are activated by a variety
of fatty acids and their derivatives such as prostaglandins [17,18].
This receptor family is comprised of three different subtypes
(PPARa, b/d, c), all of which are important regulators of lipid and
glucose metabolism in many different tissues including skeletal
muscle, liver, adipose tissue, and gut [19,20]. PPARc is found in
two different isoforms termed PPARc1 and PPARc2. The latter is al-
most exclusively expressed in adipose tissue, whereas PPARc1 is
more ubiquitously expressed. PPARs, like other nuclear receptors,
are comprised of a non-conserved N-terminal A/B domain contain-
ing the activating function 1 (AF-1), a highly conserved DNA-bind-
ing domain (DBD), a hinge region (D domain), and a C-terminal
ligand-binding domain (LBD) containing the activating function 2
(AF-2). The DBD anchors PPARs to their binding sites on the DNA
template through interactions between the two zinc ﬁngers in this
domain and the major groove of the DNA double helix [21,22].
PPARs bind as obligate heterodimers with the retinoic X receptor
(RXR) to direct hexanucleotide repeats spaced by 1 nucleotide
(DR-1) termed PPAR response elements (PPREs) [23]. AF-2 of the
PPARc LBD interacts directly with various coactivators containing
LXXLL motifs such as transcriptional intermediary factor-2 (TIF2)
[24] and Mediator subunit 1 (MED1)/thyroid hormone receptor-
associated protein 220 (TRAP220) [25,26] in a ligand-dependent
manner. In addition, AF-1 in the N-terminal A/B domain has also
been shown to interact directly with some coactivators including
p300 [27], HIV-1-Tat interactive protein 60 (Tip60) [28], and
MED14 [29] in a ligand-independent manner, and we have recently
shown that this domain is important for PPARc transactivation of a
subset of PPARc target genes [30]. Further emphasizing the impor-
tant regulatory function of the A/B domain, phosphorylation of
PPARc2 on serine 112 in this domain has been shown to both inhi-
bit and increase the transcriptional activity of the receptor depend-
ing on the cellular context [31–33]. Furthermore, it has recently
been demonstrated that the phosphorylation status of serine 16
and 21 regulates the intracellular localization of PPARc [34].
Members of the CCAAT/enhancer-binding protein (C/EBP) fam-
ily of transcription factors also play an important role in promoting
adipocyte differentiation. The C/EBPs belong to the basic leucine
zipper family and is comprised of six members, and three family
members (C/EBPa, -b, and -d) have a well established role in adipo-
genesis. C/EBPa is expressed late in adipogenesis and is a key reg-
ulator of adipocyte differentiation as evidenced by the lack of
white adipose tissue in C/EBPa/ mice [35,36]. There are two dif-
ferent isoforms of C/EBPa termed p30 and p42, respectively, with
the latter isoform being the most potent transactivator [37,38].
C/EBPb exists in three different isoforms (liver-enriched activatingprotein (LAP), LAP*, and liver-enriched inhibiting protein (LIP)).
LAP* is the most potent transactivator followed by LAP, whereas
LIP lacks the transactivation domains of LAP and LAP* and thus
may function, at least in some cases, as a dominant negative C/
EBP isoform [39,40]. C/EBPb and C/EBPd single knockout mice have
only slightly smaller white fat pads compared to wild type [41].
However, the size of the adipose tissue in double knockout mice
is signiﬁcantly reduced [41], thereby indicating important but par-
tially redundant roles of these two C/EBPs in adipogenesis. Inter-
estingly however, whereas C/EBPa is antimitotic [42–44] C/EBPb
is required for mitotic clonal expansion [45]. Furthermore, whereas
C/EBPa is required for proper development of white adipose tissue,
C/EBPb and C/EBPd appear to be more important for brown adipo-
cyte differentiation [36,41,46].
Most of our knowledge about the mechanisms of adipocyte dif-
ferentiation has been established by studying immortalized ﬁbro-
blast cell lines (e.g. 3T3-L1 and 3T3-F442A) that can be induced
to differentiate into adipocytes in vitro by the administration of a
hormonal cocktail [47,48]. From studies in these differentiation
systems, the central transcriptional network controlling adipogen-
esis has been elucidated. Within few hours after induction of dif-
ferentiation, the expression and transcriptional activity of C/EBPb
and C/EBPd are induced and these transcription factors subse-
quently induce the expression of C/EBPa and PPARc [12,49]. Fur-
thermore, the expression of C/EBPa and PPARc is sustained by a
positive feedback loop, which serves to maintain the phenotype
of the mature adipocyte [12,15,50]. In addition to these important
transcription factors, which constitute the central transcriptional
axis controlling adipogenesis, several other transcription factors
such as Krox20 [51], Krüppel-like factors [52–54], sterol-regulatory
element-binding protein (SREBP)-1c [55–57], and Stat5 [58–60]
have been shown to be important for adipocyte differentiation. A
common characteristic of all these factors is that they seem to reg-
ulate adipogenesis by regulating the expression or activity of C/
EBPb, C/EBPd, C/EBPa, and PPARc, thereby further highlighting
the central role of these key transcription factors in the transcrip-
tional cascade controlling adipocyte differentiation.
The relative importance of PPARc and C/EBPa in adipogenesis
has been investigated by elegant studies in mouse embryonic
ﬁbroblasts (MEFs) by Spiegelman and colleagues. Their results
showed that PPARc can induce adipogenesis in C/EBPa/ MEFs
in vitro [15], whereas C/EBPa is unable to do the same in
PPARc/ MEFs [50]. These results conﬁrm the central role of
PPARc in adipocyte differentiation and indicate that C/EBPa is
not obligate for activation of adipocyte speciﬁc genes, provided
PPARc is ectopically expressed [50]. However, it remains to be
investigated whether other members of the C/EBP family, like C/
EBPb and d, may be able to partially compensate for the lack of
C/EBPa – i.e. whether the C/EBPs as a family are obligate for adipo-
cyte differentiation.
3. Novel Insights from genome-wide proﬁling of PPARc binding
during adipogenesis
Fixation of living cells with formaldehyde followed by immuno-
precipitation using speciﬁc antibodies was developed more than
20 years ago as a technique to investigate protein–DNA interac-
tions in a cellular context [61]. This technique, which is now
termed chromatin immunoprecipitation (ChIP), has since been
used extensively to determine transcription factor binding to the
chromatin template within cells. Recently, ChIP has been combined
with high-throughput techniques such as tiled oligo arrays (ChIP-
chip) and deep sequencing (ChIP-seq) to get a global map of tran-
scription factor binding and distribution of histone marks (see
Fig. 1 for further explanations) [62–64]. The development of these
Fig. 1. Methods used to study genome-wide PPARc binding in adipocytes. Overview of the major steps in ChIP-chip, ChIP-seq, and ChIP-PET (Paired end diTags) technologies
used for genome-wide proﬁling of PPARc in adipocytes. In ChIP-chip (left), input and ChIP’ed DNA is labeled with ﬂuorescent dyes and hybridized to tiled oligo arrays
spanning the entire genome or deﬁned genomic regions (e.g. gene promoters). Probes are mapped to the genome and transcription factor binding sites are identiﬁed as
regions with a signiﬁcant ﬂuorescent signal in the ChIP’ed DNA sample compared to the input. ChIP-seq (middle) is fundamentally different from ChIP-chip, as the ChIP’ed
DNA is analyzed by sequencing instead of hybridization to arrays. In this method, adapters are ligated to the ChIP’ed DNA and short fragments (200–500 bp) are selected and
ampliﬁed by PCR to generate a ChIP-seq library. These fragments are hybridized to a ﬂow cell and each fragment is ampliﬁed by bridge ampliﬁcation on the ﬂow cell to
generate clusters that each originate from a single DNA fragment. The clusters are then sequenced simultaneously and sequence tags are subsequently mapped to the
genome. Peaks of sequence tags represent transcription factor binding sites. Finally, ChIP’ed DNA can be analyzed by ChIP-PET (right). In this method, ChIP’ed DNA is cloned to
yield a ChIP library. This is subsequently digested with a restriction enzyme (e.g. MmeI), blunted, and self-ligated to give a ChIP single-PET library. The paired end diTag is
then released by restriction enzyme digestion, concatenated, and cloned to give a ChIP-PET library. The paired end diTags are then sequenced and mapped to the genome. All
of the methods described above give an unbiased genome-wide proﬁle of transcription factor binding, and they have all been used to study PPARc binding in 3T3-L1
adipocytes (bottom).
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tion of transcription factor binding sites. The advantage of such ap-
proaches over in silico predictions, which only take the DNA
sequence and not the chromatin structure or other associated pro-
teins into account, are obvious [65,66]. ChIP-chip was the ﬁrst gen-
ome-wide ChIP technology to be widely employed; however, this
technique is relatively expensive to use for complete genome-wide
studies, and cross-hybridization to tiled oligo arrays may increase
the number of false positives. ChIP-seq is currently the method of
choice in transcriptional genomics as this technique is cost efﬁ-
cient, very sensitive, and has a resolution that is much higher (up
to 1 bp) than ChIP-chip. Two additional platforms for analyzing
DNA from ChIP experiments termed ChIP-cloning and ChIP-PET
(Paired end diTags) (Fig. 1) have also been used to study global
transcription factor binding [67,68] although to a lesser extent
than the two platforms described above. Both techniques offer aglobal unbiased view of transcription factor binding; however,
they employ extensive cloning of ChIP’ed DNA followed by
sequencing and are consequently more laborious than ChIP-chip
and ChIP-seq.
Given the importance of PPARc in adipogenesis, we and others
have recently determined the genome-wide binding proﬁle of
PPARc and its heterodimerization partner RXR using ChIP-seq
[69], ChIP-chip [70], and ChIP-PET [71] (Fig. 1). All studies reported
a very high degree of overlap between PPARc and RXR binding
clearly showing that PPARc associates with endogenous PPARc tar-
get sites as a heterodimer with RXR on a global scale (as exempli-
ﬁed by the stearoyl-CoA desaturase 1 (Scd1) locus in Fig. 2A). This
is in line with previous ﬁndings showing that PPARc dimerization
with RXR is obligate for direct DNA binding [72,73]. Another inter-
esting ﬁnding from these unbiased genome-wide studies is that
although PPARc:RXR binding sites are enriched at promoters, the
10 kb
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Fig. 2. Genome-wide proﬁling of PPARc binding sites in adipocyte differentiation. (A) ChIP-seq and ChIP-chip data from 3T3-L1 adipocytes viewed in the UCSC genome
browser showing PPARc- and RXR–binding sites and RNAPII occupancy for the stearoyl-CoA desaturase 1 (Scd1) locus (1Nielsen et al. 2008 ChIP-Seq [69], 2Lefterova et al.
2008 ChIP-chip [70], and 3Lefterova et al. 2010 ChIP-Seq [80]). The height of the peaks indicates the binding intensity of the factors to DNA at the respective genomic position.
Black bars for PPARc ChIP-chip data indicate peak detected target sites at day 10. (B) Venn diagram representing overlap between the three adipocyte genome-wide PPARc
binding studies shown in A (Nielsen et al. 2008, FDR < 0.1%; Lefterova et al. 2008, FDR < 1%; Lefterova et al. 2010, FDR < 0.5%). The total numbers of PPARc binding sites in the
Venn diagram from Lefterova et al. 2008 and 2010 deviate slightly from the numbers previously published [70,80] because the data was transformed from the mm8 to the
mm9 Mouse Genome Assembly.
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away from transcription start sites (TSS). Similar ﬁndings have
been reported for the estrogen receptor (ER) [65,74], glucocorticoid
receptor (GR) [75], androgen receptor (AR) [76], and vitamin D
receptor (VDR) [77], suggesting that this pattern of binding is a
general feature of several nuclear receptors and many other tran-
scription factors. Importantly, global proﬁling of H3K9 acetylation
revealed that PPARc binding sites are associated with high levels of
this activating histone mark, thereby indicating that the identiﬁed
binding sites are in fact functional regulatory sites [70]. These ﬁnd-
ings show that PPARc as well as other nuclear receptors act at a
distance from target gene promoters and suggest that looping be-
tween enhancer elements and promoters is a common mechanism
of PPARc transactivation of target genes, as has been demonstrated
for ER [78]. In keeping with this, we have recently shown that an
enhancer in intron 1 of the uncoupling protein (UCP) 3 not only
regulates expression of UCP3 but also loops down to speciﬁcally
interact with and most likely activate the adjacent UCP2 gene pro-
moter [79].The overlap between PPARc binding from Nielsen et al. 2008
[69], Lefterova et al. 2008 [70], and Lefterova et al. 2010 [80] is
shown for the Scd1 locus in Fig. 2A and by a genome-wide Venn
diagram in Fig. 2B. These studies reveal that 1634 PPARc target
sites are found in mature 3T3-L1 adipocytes irrespective of the lab-
oratory, ChIP detection method, and peak detection program. This
pool of PPARc binding sites thus represents high-conﬁdence bind-
ing sites occupied by PPARc in adipocytes. Interestingly, it also
shows that in total 9132 PPARc sites have been detected by the
two laboratories, showing that the number of sites that can be
associated with PPARc in adipocytes is much higher than the num-
ber of high-conﬁdence sites. This indicates that other factors (e.g.
transcription factors, cofactors, epigenetic factors) might inﬂuence
the PPARc cistrome and thereby ﬁne tune PPARc action in
adipocytes.
Two other recent studies used ChIP in combination with tiled
oligo promoter arrays to identify PPARc binding sites during adipo-
genesis (Fig. 1). Nakachi et al. [81] used this approach together
with microarray gene expression analysis to identify 20 genes that
Adipogenesis
PPARγ
C/EBPα
C/EBPβ 
C/EBPδ Adipocyte genes
PPARγ:RXR C/EBPα:C/EBPα
1.4 sites/gene
2.0 sites/gene
1
DR-1 consensus C/EBP consensus
Highly induced genes
Modestly induced genes
1.0 site/gene
1.0 site/gene
Fig. 3. C/EBP and PPARc crosstalk during adipogenesis. (A) Web logo of DR-1 type PPRE and C/EBP consensus motif Position Weight Matrix (PWM) generated based on de
novo motif search of PPARc:RXR–binding sites (Nielsen et al. 2008 [69]). (B) Schematic overview of the transcriptional network controlling adipogenesis (left) and prevalence
of common PPARc:RXR–C/EBP sites within 100 kb of the TSS of genes in RNAPII cluster D (highly upregulated genes) and E (modestly upregulated genes) (Nielsen et al. 2008
[69]) (right).
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during 3T3-L1 adipocyte differentiation. Sixteen of these genes
were novel PPARc target genes. Wakabayashi et al. [82] identiﬁed
2730 PPARc target sites in mature 3T3-L1 adipocytes using a pro-
moter array tiling from 6 kb to +2.5 kb relative to the TSS of
28 000 mouse proximal promoters. Interestingly, they combined
binding information from the PPARc ChIP-chip with gene expres-
sion data and identiﬁed a cluster of eight genes encoding protein
methyltransferases containing SET domains as direct PPARc target
genes during adipogenesis. One of these termed Setd8 was shown
to be important for PPARc target gene activation and adipogenesis
by increasing H4K20 mono-methylation at PPARc target genes.
These ﬁndings indicated a positive feedback loop between PPARc
and SET domain methyltransferases that may be important for adi-
pocyte differentiation.
4. PPARc activates most genes linked to adipogenesis and
metabolism
RNAPII occupancy at ER target gene promoters as determined
by ChIP in combination with tiled oligo promoter arrays has previ-
ously been used to study gene transcription in response to estro-
gen treatment [83]. We have recently used ChIP-seq to
determine the genome-wide occupancy of RNAPII during adipo-
genesis and used RNAPII occupancy within genes as a measure of
transcriptional activity [69]. Brieﬂy, sequence tags from +250 to
the end of Ensembl genes were counted on the different days of
differentiation for all genes >1 kb in length, and the number of se-
quence tags within each gene was expressed relative to the num-
ber at day 0 of differentiation and was used a measure of relative
transcription level. In these analyses, promoter regions were omit-
ted to avoid including tags from RNAPII stalled at the promoter.
RNAPII occupancy within genes was shown to correlate well with
primary transcript levels as measured by qPCR using intron-exonprimers (Median Spearman correlation factor 0.83). Cluster analy-
sis of the regulated genes identiﬁed ﬁve distinct clusters based on
their temporal proﬁle of RNAPII occupancy (i.e. transcription) dur-
ing differentiation. Genes in clusters A and B were linked to cell cy-
cle and cell proliferation and downregulated during adipogenesis.
Genes in cluster C were linked to cell cycle and the ribosome and
were transiently upregulated and then downregulated later in
the differentiation process. Finally, genes in cluster D and E were
linked to glucose and lipid metabolism and upregulated during dif-
ferentiation. Assigning peaks to the nearest gene revealed that
PPARc:RXR sites in mature adipocytes are associated with 74%
and 47% of the upregulated genes in cluster D and E, respectively,
thereby suggesting that PPARc is involved in the induction of a
hitherto unrecognized high number of genes activated during adi-
pogenesis. Notably, almost all genes involved in lipid and glucose
metabolism had PPARc:RXR target sites assigned. These ﬁndings
were supported by the Lazar group who showed that 63% of the
genes that are upregulated more than threefold during adipogene-
sis, as determined by gene expression microarray, have at least one
PPARc binding site within 50 kb of their TSS [70]. Both studies also
showed that a subset of these binding sites can drive gene expres-
sion in a heterologous promoter reporter assay. Furthermore,
knockdown of PPARc expression using siRNA approaches or activa-
tion of PPARc by its high-afﬁnity ligand rosiglitazone was demon-
strated to decrease and increase expression of these genes,
respectively [69,70]. These ﬁndings indicate that PPARc in addition
to being a central coordinator of the adipogenic program also acts
as a direct activator of most adipocyte speciﬁc genes.
5. PPARc and C/EBPa bind adjacent on a genomic scale in
adipocytes
Motif analyses on the DNA sequences from PPARc:RXR binding
sites in mature adipocytes revealed that the DR-1 type PPRE
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by in vitro studies [72,73], is highly enriched at PPARc:RXR binding
sites [69,70] (Fig. 3A). PPARc has also been shown to associate with
DR-2 elements in vitro [84]; however, DR-2 elements were not
found to be enriched at PPARc:RXR target sites, thereby indicating
that the DR-1 element is the main motif directing PPARc action in
adipocytes.
Interestingly, both Lefterova et al. [70] and Nielsen et al. [69] re-
ported the enrichment of a C/EBP binding motif at PPARc target
sites in addition to the DR-1 element, suggesting that these adipo-
genic transcription factors work together at common regulatory
sites to regulate target genes (Fig. 3A). C/EBPa ChIP at a few se-
lected loci conﬁrmed that C/EBPa and PPARc do occupy some of
the same sites in mature adipocytes [69]. These ﬁndings were ex-
tended by Lefterova et al. [70], who showed that 63% of the PPARc
target sites identiﬁed by ChIP-chip in mature adipocytes were also
bound by C/EBPa, thereby identifying a novel direct crosstalk be-
tween these two key adipogenic transcription factors at common
regulatory sites on a global scale. Interestingly, C/EBPb, which is
important early in adipogenesis has a binding proﬁle similar to
C/EBPa in mature adipocytes [70]. Importantly, knock down of
any of these two C/EBP family members or PPARc in mature adipo-
cytes, reduced the expression of genes associated with common
PPARc:RXR–C/EBP binding sites. This suggests that crosstalk be-
tween PPARc:RXR and C/EBPs at common regulatory sites is
important for regulating the expression of adipocyte genes
(Fig. 3B). Interestingly, genes contained in RNAPII cluster D de-
scribed above, which are highly induced during adipogenesis, have
on average two common PPARc:RXR–C/EBPa sites within 100 kb of
their TSS, whereas genes in cluster E only have one common site on
average in the proximity of their TSS (Fig. 3B). This may at least
partly explain why genes in cluster D are more highly induced than
genes in cluster E, and it suggests that the crosstalk between C/
EBPs and PPARc is especially important for the induction of the
highly induced adipocyte genes.
The ﬁnding that PPARc and C/EBPs occupy the same regulatory
sites and directly coordinate the expression of most adipocyte
genes has important implications for our understanding of the
transcriptional network controlling adipogenesis. Although it is
evident that PPARc is a key regulator of adipogenesis, the data
from the genome-wide analyses described above indicate that
members of the C/EBP family may directly promote or modulate
PPARc activity at the majority of its binding sites. Interestingly,
the co-occupancy of C/EBPs with PPARc in adipocytes is not re-
stricted to C/EBPa, since C/EBPb is also bound to many target sites
even in the mature adipocytes [69,70]. This indicates that C/EBPb,
in addition to being an early inducer of PPARc expression, may also
cooperate with PPARc in mature adipocytes (Fig. 2B). Furthermore,
C/EBPb occupies many PPARc target sites prior to binding of PPARc
[69], indicating that this subtype may also function as a priming
factor preparing the chromatin template for PPARc. The partial
redundancy between the C/EBP subtypes may have made it difﬁ-
cult to observe such functions of C/EBPs in previous genetic stud-
ies. Further investigations are necessary to delineate the
functional and molecular relationship between members of the
C/EBP family and PPARc on common regulatory target sites of adi-
pocyte genes.6. Concluding remarks
The recent genome-wide studies discussed in this review have
greatly increased our understanding of the mechanisms underlying
PPARc action during adipogenesis. Most interestingly, these stud-
ies have revealed a novel crosstalk between PPARc and C/EBPs,
which has revised our view on the transcriptional network control-ling adipogenesis and adipocyte function. Concurrently, these
studies have inspired new interesting questions. First, how do
PPARc and C/EBPs work together on the chromatin template? In
particular, it will be interesting to investigate if they occupy com-
mon sites at the same time as a part of the same complex or if they
work in a sequential manner. In this regard, it is interesting to
speculate that PPARc and C/EBPs directly interact as has been dem-
onstrated for C/EBPs and several other nuclear receptors including
GR and PPARa [85,86]. Second, how do epigenetic marks and the
chromatin structure change at common PPARc:RXR–C/EBP sites
during adipogenesis? Given the early binding of C/EBPb to com-
mon PPARc:RXR–C/EBP sites, it will be especially interesting to
investigate how the chromatin landscape changes early in adipo-
genesis and how this affects PPARc target gene activation. Finally,
are other transcription factors directly involved in the PPARc:RXR–
C/EBP crosstalk? In this regard, the Krüppel-like factor (Klf) family
of transcription factors is of particular interest, as several members
of this family have been shown to be involved in adipocyte differ-
entiation [52–54]. It is likely that a more extensive crosstalk
involving several adipogenic transcription factors will be revealed
as more genome-wide proﬁles emerge in the near future.
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